Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

The objectives of this analysis were to develop a population pharmacokinetics (PK) model of durvalumab, an anti‐PD‐L1 antibody, and quantify the impact of baseline and time‐varying patient/disease characteristics on PK. Pooled data from two studies (1,409 patients providing 7,407 PK samples) were an...

Descripción completa

Detalles Bibliográficos
Autores principales: Baverel, Paul G., Dubois, Vincent F.S., Jin, Chao Yu, Zheng, Yanan, Song, Xuyang, Jin, Xiaoping, Mukhopadhyay, Pralay, Gupta, Ashok, Dennis, Phillip A., Ben, Yong, Vicini, Paolo, Roskos, Lorin, Narwal, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887840/
https://www.ncbi.nlm.nih.gov/pubmed/29243223
http://dx.doi.org/10.1002/cpt.982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887840/
https://www.ncbi.nlm.nih.gov/pubmed/29243223
http://dx.doi.org/10.1002/cpt.982

Ejemplares similares